UPNEEQ (nda212520)- (0.1%)

Generic Name	OXYMETAZOLINE HYDROCHLORIDE	Innovator	RVL PHARMS
Dosage	0.1%
ParaIV Filing	No	505(b)2 Filing	Yes
Last Patent Expiry	2039-Dec-16	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	2023-Jul-08
GAIN Expiry	None	Drug Complexity	No
Indication	UPNEEQ is indicated for the treatment of acquired blepharoptosis in adults.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	1

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.1%	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
No	0

Manufacturing Details of UPNEEQ